
Sign up to save your podcasts
Or


Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA.
The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.
This week, we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR.
01:15-02:51: Dr Xi’s background
02:51-05:11: The beginning of Epic Bio
05:12-09:23: What is epigenetic editing?
09:23-10:47: What is the Gene Expression Modulation System?
10:47-12:47: How is the editing reversible?
12:47-18:01: How will epigenetic editing advance treatments?
18:01-21:24: Tackling multiple conditions
21:24-22:46: How will your platform tackle FSHD?
22:46-24:18: FSHD clinical trial
24:18-25:51: How will you address costs?
25:51-27:18: Are other companies working on epigenetics?
27:18-29:27: What else is in the pipeline?
29:27-31:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
By Labiotech3.3
33 ratings
Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA.
The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.
This week, we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR.
01:15-02:51: Dr Xi’s background
02:51-05:11: The beginning of Epic Bio
05:12-09:23: What is epigenetic editing?
09:23-10:47: What is the Gene Expression Modulation System?
10:47-12:47: How is the editing reversible?
12:47-18:01: How will epigenetic editing advance treatments?
18:01-21:24: Tackling multiple conditions
21:24-22:46: How will your platform tackle FSHD?
22:46-24:18: FSHD clinical trial
24:18-25:51: How will you address costs?
25:51-27:18: Are other companies working on epigenetics?
27:18-29:27: What else is in the pipeline?
29:27-31:58: What are the next steps?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter

43,597 Listeners

538 Listeners

2,691 Listeners

2,452 Listeners

125 Listeners

320 Listeners

62 Listeners

5,545 Listeners

86 Listeners

34 Listeners

501 Listeners

148 Listeners

15,938 Listeners

18 Listeners

96 Listeners